Cash Flow Statement

Amortizatization of Intangibles Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Accured Expenses Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation and Depletion Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Net Cash Flow Net Income Non-cash Items Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Stoke Therapeutics (STOK) Asset Writedowns and Impairment (2025)

Historic Asset Writedowns and Impairment for Stoke Therapeutics (STOK) over the last 1 years, with Q3 2025 value amounting to $700000.0.